Efficacy of tulathromycin injectable solution for the treatment of naturally occurring Swine respiratory disease.
Tulathromycin, a novel triamilide antimicrobial, was evaluated for treatment of swine respiratory disease (SRD) in field efficacy studies involving 720 pigs in six North American swine herds. In each study, feeder pigs with clinical SRD were randomly assigned in equal numbers to a group treated with tulathromycin given as a single injection at 2.5 mg/kg of body weight or to a saline-treated control group. Four of the studies included a third group treated with ceftiofur sodium for 3 consecutive days at 3 mg/kg of body weight. Pigs were treated on day 0 and evaluated for treatment response on day 7. In each study, 10 or more nontreated pigs and saline-treated pigs that did not respond to treatment underwent necropsies to obtain lung samples that were evaluated for SRD pathogens. The overall cure rate was 46.4% for saline-treated pigs, 71.1% for tulathromycin-treated pigs, and 63.1% for ceftiofur-treated pigs. The cure rate for tulathromycin-treated pigs was significantly higher than for saline-treated pigs (P = .0116). Mortality from SRD occurred in 24 control pigs, seven tulathromycin-treated pigs, and one ceftiofur-treated pig. The mortality rate was significantly lower for both the tulathromycin- and ceftiofur-treated pigs compared with those treated with saline (P = .0148 and P = .0195, respectively). Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, and Mycoplasma hyopneumoniae, bacteria commonly associated with SRD, were isolated from SRD-affected pigs. Under field conditions, tulathromycin injectable solution given as a single IM dose of 2.5 mg/kg of body weight was safe and effective in the treatment of SRD.
Nutsch
Robert G
RG
Pfizer Animal Health, Veterinary Medicine Research and Development, Kalamazoo, MI 49001, USA.
Hart
Fred J
FJ
Rooney
Kathleen A
KA
Weigel
Daniel J
DJ
Kilgore
W Randal
WR
Skogerboe
Terry L
TL
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use; D004187:Disaccharides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007273:Injections, Intramuscular / Q000662:veterinary; D008297:Male; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D045705:Mycoplasma hyopneumoniae / Q000187:drug effects; D012766:Pasteurellosis, Pneumonic / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D012720:Severity of Illness Index; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D016896:Treatment Outcome; D014481:United States; D018942:Macrolides
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004187:Disaccharides; D006571:Heterocyclic Compounds; C053503:ceftiofur; C485204:tulathromycin; D018942:Macrolides